The combination of in vitro investigations, the zebrafish screening model and rodent experiments offered a unique approach to optimizing nanoparticles modified with Hepatitis B virus-derived peptides to specifically target hepatocytes.

Human liver organoids provide a patient-derived platform to interrogate host and viral mechanisms of HBV replication, perform anti-HBV and toxicity drug screens, and investigate the molecular determinants of related tumorigenesis.

A novel and potent receptor-binding-blockage human neutralizing antibody prevents HBV infection, and suppresses HBV infection therapeutically in HBV-infected mice.